Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$12.39 USD
-0.05 (-0.40%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $12.40 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RCUS 12.39 -0.05(-0.40%)
Will RCUS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCUS
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
Pacira (PCRX) Tops Q2 Earnings Estimates
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?
Other News for RCUS
RCUS's price falls by 0.4% on September 20, though its technical setup remains stable.
RCUS forms Stochastic Reached Overbought on September 19
Technical picture remains unchanged for RCUS after it rises 2.38% on September 18
The technical outlook for RCUS is unchanged after it rises 1.47% on September 16
RCUS's price rises by 0.52% on September 15, though its technical setup remains stable.